These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6580646)

  • 1. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
    Ebert RF; Bell WR
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II.
    Borrell M; Vila L; Solá J; Coll I; Gómez N; González N; Rutllant ML
    Thromb Res; 1987 Mar; 45(5):591-9. PubMed ID: 3109061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization.
    Ruf W; Bender A; Lane DA; Preissner KT; Selmayr E; Müller-Berghaus G
    Biochim Biophys Acta; 1988 May; 965(2-3):169-75. PubMed ID: 3365451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
    Branson HE; Schmer G; Theodor I; Pirkle H
    Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
    Vila V; Regañón E; Aznar J; Navarro G; Salas M
    Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.
    Martinez J; Holburn RR; Shapiro SS; Erslev AJ
    J Clin Invest; 1974 Feb; 53(2):600-11. PubMed ID: 11344575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
    Ebert RF; Schreiler WE; Bell WR
    Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
    Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
    Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'.
    Okumura N; Terasawa F; Haneishi A; Fujihara N; Hirota-Kawadobora M; Yamauchi K; Ota H; Lord ST
    J Thromb Haemost; 2007 Dec; 5(12):2352-9. PubMed ID: 17922804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen Mahdia: A congenitally abnormal fibrinogen characterized by defective fibrin polymerization.
    Amri Y; Jouini H; Becheur M; Dabboubi R; Mahjoub B; Messaoud T; Sfar MT; Casini A; de Moerloose P; Toumi NEH
    Haemophilia; 2017 Jul; 23(4):e340-e347. PubMed ID: 28594476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
    Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The release of small amounts of fibrinopeptide-B (FPB) is of critical importance for the thrombin clotting time.
    Holm B; Kierulf P; Godal HC
    Thromb Res; 1986 May; 42(4):517-26. PubMed ID: 3715815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.